{"entity":{"id":"prtx007","kind":"drug","name":"PRTX007","aka":[],"tldr":"PRTX007 is a small-molecule inhibitor from Primmune Therapeutics, Inc., in registered phase 2 trials for melanoma.","summary":"PRTX007 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Primmune Therapeutics, Inc., in melanoma. Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of PRTX007","url":"https://clinicaltrials.gov/search?intr=PRTX007"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07565285"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"PRTX007","modality":"Small-molecule inhibitor","mechanism":"Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/prtx007/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"trial":[{"id":"nct07565285","kind":"trial","name":"The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma","route":"/trials/nct07565285/"}]}}